|
|||||
|
|
A phase II study of thioTEPA in children with recurrent solid tumor malignancies: a Children's Cancer Group study |
|
| Authors: | J. Russell Geyer Frank M. Balis Mark D. Krailo Richard Heideman Emmett Broxson Judith K. Sato David Poplack W. Archie Bleyer |
| Affiliation: | (1) Children 's Hospital and Medical Center, University of Washington, Seattle, Washington;(2) National Cancer Institute-NIH, Bethesda, Maryland;(3) University of Southern California School of Medicine, Los Angeles, California;(4) St. Jude Children's Research Hospital, Memphis, Tennessee;(5) Wright Patterson AFB, Dayton, Ohio;(6) Childrens Hospital of Los Angeles, Los Angeles, California;(7) Texas Children's Cancer Center, Houston, Texas;(8) M.D. Anderson Cancer Center, University of Texas, Houston, Texas, USA |
| Abstract: | Summary A Phase II study of thioTEPA was performed by the Children's Cancer Group. ThioTEPA was administered intravenously every three weeks, at a dose of 65 mg/m2. Pediatric patients with recurrent sarcomas were targeted, but patients with other tumor diagnoses were also eligible. Toxicity was primarily hematopoietic, with thrombocytopenia being predominant. ThioTEPA did not demonstrate significant activity in the target tumor groups evaluated. |
| Keywords: | thioTEPA alkylating agents sarcomas chemotherapy |
| 本文献已被 SpringerLink 等数据库收录！ | |